Question 1

What is PT-141?

Accepted Answer

PT-141 (bremelanotide) is a cyclic melanocortin analog derived from Melanotan II with agonist activity at MC3R and MC4R receptors. It has been studied in preclinical pharmacology for melanocortin receptor characterization and in clinical trials leading to FDA approval in 2019 as Vyleesi. The compound acts centrally through hypothalamic melanocortin receptor activation, distinguishing its mechanism from peripherally-acting compounds studied for related endpoints. PT-141 is for in vitro research use only.

Question 2

How does PT-141 work in research models?

Accepted Answer

In preclinical research models, PT-141 activates MC3R and MC4R receptors in hypothalamic nuclei through Gs protein coupling and downstream cAMP signaling. Animal neuroanatomy studies using c-Fos immunohistochemistry have documented activation of specific hypothalamic nuclei including the paraventricular nucleus and medial preoptic area. The central mechanism distinguishes PT-141 from peripherally-acting approaches to related research endpoints. See /how-pt-141-works/ for the complete mechanism overview.

Question 3

What has PT-141 been studied for in published research?

Accepted Answer

Published research has examined PT-141 in melanocortin receptor pharmacology studies (binding affinity and selectivity profiles), hypothalamic neuroanatomy using c-Fos activation mapping, cardiovascular pharmacology studies characterizing blood pressure effects, Phase II and III clinical trials leading to 2019 FDA approval, and comparative mechanistic studies versus peripherally-acting compounds at related research endpoints.

Question 4

What is PT-141's half-life in research models?

Accepted Answer

Published pharmacokinetic data from clinical studies documents PT-141 with a plasma half-life of approximately 2.7 hours in human pharmacokinetic characterization from clinical trial data. This relatively extended half-life compared to linear melanocortin peptides is attributed to the cyclic peptide structure providing resistance to proteolytic degradation. Published preclinical pharmacokinetic data in rodent models should be consulted for species-specific parameters.

Question 5

How is PT-141 stored for research use?

Accepted Answer

Research-grade PT-141 should be stored as lyophilized powder at -20 degrees Celsius for long-term stability. Reconstituted solutions should be stored at 2 to 8 degrees Celsius and used within the handling period specified by the supplier. The cyclic structure provides some stability advantages over linear peptides, documented in published stability characterization. For in vitro receptor pharmacology research, freshly prepared solutions at defined concentrations are standard practice.

Question 6

What purity standard should research-grade PT-141 meet?

Accepted Answer

Research-grade PT-141 should meet at least 98% purity by HPLC analysis with mass spectrometry molecular weight confirmation of the cyclic peptide structure. The cyclic disulfide bond should be confirmed in COA mass spectrometry data. Certificate of Analysis should include purity result and batch identification. Researchers should verify the cyclic versus linear form specification, as linear analogs would have different receptor pharmacology profiles.

Question 7

What cardiovascular safety considerations appear in published PT-141 research?

Accepted Answer

Published clinical PT-141 research and FDA approval documentation characterize transient blood pressure changes following administration, which led to the inclusion of cardiovascular contraindications and monitoring requirements in published prescribing information. Researchers designing in vivo studies should incorporate cardiovascular parameter monitoring consistent with published clinical methodology. This is not unique to PT-141; multiple melanocortin agonists have documented cardiovascular effects in published pharmacology research.

Question 8

What is the significance of the 2019 FDA approval for PT-141 research?

Accepted Answer

The 2019 FDA approval of bremelanotide as Vyleesi for hypoactive sexual desire disorder in premenopausal women represents one of the most clinically complete regulatory approvals for a melanocortin research peptide. The published Phase III trial data, pharmacokinetic characterization, and safety database generated through the approval pathway provide researchers with reference parameters not available for most research peptides. Published FDA regulatory documentation is publicly accessible through the FDA drug database.

Question 9

How does PT-141 compare to Kisspeptin in reproductive research?

Accepted Answer

PT-141 and Kisspeptin address reproductive biology through different receptor systems in published research. PT-141 acts through hypothalamic MC3R and MC4R receptors with autonomic signaling effects. Kisspeptin acts through GPR54 on GnRH neurons, governing pulsatile GnRH and gonadotropin release. The research bodies for these two compounds address complementary but distinct aspects of reproductive neuroendocrinology and have been studied in different primary model systems.

Question 10

Where can researchers source PT-141 for in vitro research?

Accepted Answer

Research-grade PT-141 for in vitro receptor pharmacology and cell culture research is available from Spartan Peptides with at least 98% HPLC-verified purity and Certificate of Analysis documentation. All PT-141 is for in vitro research use only. Researchers should confirm cyclic peptide form and disulfide bond integrity through COA mass spectrometry data before using PT-141 in receptor binding or functional assay applications.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research

PT-141 Frequently Asked Questions

Explore Full Research Index